Pharmaceutical Industry discussion, review, analysis, news and information. |
archives
- About Lorenzo's Oil
- Pfizer’s Novel HIV/AIDS Drug Maraviroc, Under Accelerated Review in US and EU Regulatory Agencies
- GSK Access Offers Free Prescription Medicines to Eligible Medicare Part D-Enrolled Patients
- Nexavar® Passed Phase III Clinical Trial in Primary Liver Cancer Patients
- ViroPharma’s Maribavir, Granted USFDA Orphan Drug Designation for Cytomegalovirus Viremia and Disease Indication
- Anesiva’s New Drug Application (NDA) of Zingo™ for Reduction of Needle Insertion-Painin Children, Accepted by the USFDA
- Corautus Genetics and VIA Pharmaceuticals Agreed on a Merger
- Lupin’s Sertraline, Approved by the USFDA
- Sanofi-aventis’ sNDA of Lovenox® (Enoxaparin Sodium Injection) for Acute Heart Attack Under USFDA Priority Review
- Pfizer’s Sutent® (sunitinib malate) USFDA-Approved to Include New First-Line Advanced Kidney Cancer Data in Product Label
- ImmuneRegen's Viprovex™ Demonstrated Potential in Treatment of Avian Influenza and Spanish Flu
- 2007 Shingo Prize for Excellence in Manufacturing Goes to Two Baxter Int’l. Facilities
- Pharmacokinetics of KADIAN® (morphine sulfate extended-release), Not Significantly Affected by Alcohol Consumption
- Alphanate, New Product USFDA-Approved for von Willebrand Disease
- Ranbaxy Signed New R&D Agreement with GlaxoSmithKline
- WEHI and Genentech Collaboration, To Develop New Cancer Drugs
- BioCryst’s Fodosine™, Granted EMEA Orphan Drug Status for Cutaneous T-cell Lymphoma (CTCL)
- AXM Shengyang Acquires Yuhuatang
- ImClone and Bristol-Myer Squibb’s ERBITUX ®, under Japanese PMDA Evaluation for Treatment of Advanced Colorectal Cancer
- elbion NV and Wyeth to Develop New Treatments for Schizophrenia
- Cervical Cancer Vaccination: A Mandate in Texas State
- Wyeth Pharmaceuticals and Nautilus Biotech Collaborates for Development of Hemophilia Therapies
- Majority Stake in Beijing Boran Pharmaceutical, Acquired by China Health Holding
- CSL Behring and Bayer Healthcare Agreed to Extend Agreement for Supply of Helixate® Recombinant Coagulation Factor
- China’s Aida Pharmaceuticals won Etimicin Sulfate Patent Lawsuit
- Genentech’s Raptiva® (efalizumab) Passed Phase IV Study in Moderate-to-Severe Hand and Foot Psoriasis Patients
- New Dosing Recommendations for RAPAMUNE® (sirolimus) in High Immunologic Risk Renal Transplant Patients, Approved by the USFDA
- Anacor Signed Worldwide Exclusive License Agreement with Schering-Plough for New Topical Anti-Fungal, AN2690
- Pfizer Agreed to Acquire BioRexis Pharmaceutical
- Acquisition of Arrow Therapeutics Broadens AstraZeneca’s Anti-Infective Portfolio
- MediVas Collaborates With Merck in Area of Biologics
- USFDA Accepted Pharmion’s IND for Oral Azacitidine (Vidaza®)
- AstraZeneca and Palatin Technologies Collaborates to Discover, Develop and Commercialise Small Molecule Obesity Compounds
- Institute of Materia Medica and TB Alliance Will Develop Improved TB Drugs
- Patent for Heat Shock Protein (Hsp) Fusion for Flu Treatment, Awarded to Nventa Biopharma
- Laureate Pharma in Manufacturing Agreement with Trubion Pharmaceuticals
- Novo Nordisk’s NovoLog® (insulin aspart [rDNA origin] injection), FDA-Approved for Use in Pregnant Women with Type 1 Diabetes
- Alfacell Corp.’s ONCONASE®, Received U.S. Orphan Drug Designation for the Treatment of Malignant Mesothelioma
- Spatially Offset Raman Spectroscopy: Novel Non-Invasive Method of Detection of Counterfeit Drugs
- Debiopharm Entered Into R&D and Commercialisation Agreement with Kirin for Debio-0719
- The USFDA is Too Slow to Approve New Drugs and Devices, New Physician Survey Finds
- iCardiac Technologies Signed Cardiac Safety Alliance With Pfizer
- Pharmion Corp.’s Vidaza® (azacitidine for injection), USFDA-Approved for I.V. Administration
- Berlex, Inc.’s YAZ®, USFDA-Approved for New Indication: Treatment of Acne
- Copegus® Tablet 200 mg, Approved as Combination Therapy to Chronic Hepatitis C Drug Pegasys®
- Bayer Schering Pharma AG’s Oral Fludara®, Approved in Japan
- Sanofi pasteur’s New Pediatric Combination Vaccine (Pentacel®): Recommended for Licensure by USFDA Advisory Committee
- NF-kB Inhibitors: New Class of Drugs Potentially Anti-Alzheimer’s Disease
- Topical Eutectic Mixture, Found Safe and Effective Against Premature Ejaculation
- Beta Blockers: Not The Best First-line Treatment of HIgh Blood Pressure
- Small Molecule Now, Diabetes and Obesity Pill Tomorrow
- MediVas Signed Collaboration Agreement With Pfizer
- Roche’s ACTEMRA™ (tocilizumab) Passed Phase III Study in Rheumatoid Arthritis Patients
- Medarex and Compugen Collaborates to Develop Antibody-Based Therapeutics
- Pharmion Submitted EU Marketing Authorization Application for Thalidomide Pharmion® for Untreated Multiple Myeloma
- Wyeth Pharmaceuticals Received USFDA Approvable Letter for Pristiq™ (desvenlafaxine succinate) as Treatment for Adult Major Depressive Disorder (MDD) Patients
- Ortho Biotech Submitted USFDA sNDA for DOXIL® as Combination to VELCADE® for Treatment of Relapsed/Refractory Multiple Myeloma
- SQ109: Sequella, Inc.’s TB Drug Candidate, Received USFDA Fast Track Status
- Bioponic Phytoceuticals’ Curecumin™ Product Potentially Effective Against Alzheimer's Disease (AD)
- Cell Genesys, Inc.’s GVAX® Immunotherapy Passed Follow-Up Phase 2 Clinical Trial for Pancreatic Cancer
- International Phase III Study Revealed That XELOX (Xeloda® + oxaliplatin) Equals FOLFOX in Overall Patient Survival From Advanced Colorectal Cancer
- Prilosec OTC: As Effective as Prescription Drugs for Heartburn and Acid Reflux Disease
- BioMS Medical Corp. Received USFDA Clearance to Commence Phase III Multiple Sclerosis Trial
- New Imaging Compounds for Detection of Neurodegenerative Diseases To be Developed by Bayer Schering Pharma
- Generic METAGLIP™ Tablets, Launched by Barr Labs
- Barr Labs Received USFDA Tentative Approval for Generic KYTRIL® (granisetron hydrochloride) Tablets, 1mg (base)
- TAXUS® Stent System Expiration Date Extended to 18 Months by USFDA
- H. Lundbeck A/S’ Cipralex® (escitalopram), Approved in Europe for Treatment of OCD (Obsessive Compulsive Disorder)
- Carrington Laboratories Entered Supply and Trademark Agreement with Veterinary Products Laboratories for Acemannan Immunostimulant™
- Archemix and Merck KGaA Collaborates on Development and Marketing of Aptamer-Based Cancer Therapeutics
- Cepheid and bioMerieux Agreed to Develop and Market Sepsis and MRSA Products
- Metabolex, Inc.’s MBX-102/JNJ-39659100 (metaglidasen) Reduced Inflammation in Preclinical Diabetes Models
- VioQuest Pharma’s VQD-001 ((sodium stibogluconate) Granted USFDA Orphan Drug Designation for the Treatment of Cutaneous Form Leishmaniasis
- Sirion Therapeutics Acquired U.S. License of Virgan® (ganciclovir gel), Opthalmic Anti-viral
- Green Tea is Source Of Potential Potent and Safe Antibacterial
- Denderon Corp.’s BLA for PROVENGE® under USFDA Priority Review Status for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer
- XTL and DOV Pharmaceuticals, Agreed on Worldwide Rights to Bicifadine
- Merck Serono’s Phase III Diet Study of Phenoptin for Phenylketonuria Yielded Positive Results
- Watson Pharma’s Silodosin Passed Phase III Clinical Trials for Treatment of Benign Prostatic Hyperplasia
- Merger with Genentech, Approved by Stockholders of Tanox, Inc.
- Lux Biosciences Received USFDA Orphan Drug Designation for Ophthalmic Indications of ISA247
- Long Term Dose-dependent Use of Genzyme Corp.’s Cerezyme® (imiglucerase for injection), Improve Bone Mineral Density in Type 1 Gaucher Disease Patients
- Canadian Marketing Rights to Xyrem®, Signed By Jazz Pharmaceuticals With Valeant Pharmaceuticals
- Peregrine Pharmaceuticals Established Chinese Subsidiary
- ERBITUX® Passed Phase III Study as First-Line Treatment of Metastatic Colorectal Cancer
- AMDL is Producing Antibiotic Levofloxacin in China
- Wyeth and Solvay Pharmaceuticals Agreed on Additional Neuroscience Collaboration
- Bristol-Myers Squibb and AstraZeneca Entered Into Worldwide Collaboration For the Development and Commercialization of Diabetes Compounds
- Warning from National Association of Boards of Pharmacy: Beware of Continued Dangers of Counterfeit Prescription Drugs
- First and Only Enzyme Replacement Therapy for Hunter Syndrome: Approved by the European Commission
- Neurocrine Biosciences’ Orally Active GnRH Receptor Antagonist in Endometriosis, Passed Second Phase II Clinical Trial
- Provectus’ Anti-Cancer Agent (PV-10) Received USFDA Orphan Drug Designation for the Treatment of Metastatic Melanoma
- Horizon Therapeutics’ Special Protocol Assessment (SPA) Phase 3 Trial Program of GI-Friendly Prescription NSAID, Approved by the USFDA
- QIAGEN and Pathway Diagnostics In Agreement to Address Pharma’s Biomarker Development Needs
- Genentech, Made it Once More to FORTUNE’s ‘100 Best Companies To Work For’
- PTC Therapeutics Entered Into a Strategic Drug Discovery Collaboration with Pfizer
- Hypnion’s Novel Sleep Drug – HY10275 – Passed Phase II Clinical Trial
- Pfizer Animal Health’s Slentrol™: First USFDA-Approved Anti-Obesity Drug for Dogs
- Serono S.A.’s Majority Share, Acquired by Merck KGaA
- Helix BioPharma Corp. Signed L-DOS47 Manufacturing Aagreement with BioVectra dcl
- ActiveSight Entered Multi-Target Crystallography Service Agreement With Lexicon Pharmaceuticals
- Provid Signed Agreement to Acquire Tripos Discovery Research
- Genentech’s Pertuzumab in Combination with Gemcitabine Passed Phase II Trial for Advanced Ovarian Cancer
- Anthera Received USFDA Approval to Initiate A-002 Phase 2 'PLASMA' Trial in Patients with Coronary Atherosclerosis
- Roche and Synosis Therapeutics Entered Partnership to Explore Potential of Five Central Nervous System-Targeted Compounds
- US$4.8 Million Biodefense Research Contract Awarded to Affinium Pharmaceuticals by United States Department of Defense/DTRA
- Schering-Plough and OraSure Technologies Sealed Agreement for Development and Promotion of Rapid Point-Of-Care Oral Hepatitis C Test
- Exclusive Worldwide License Rights to Develop and Commercialize Promising Phase II Spinal Cord Injury Drug, Cethrin®, Acquired by Boston Life Sciences
- Elusys Therapeutics, Inc. Sealed Collaborative Research and License Agreement with Pfizer
- AVEO Pharma, Inc. Acquired Kirin’s Clinical Stage Anti-Cancer Compound, KRN951
- HHS Granted $102.6 M Fund to BioCryst Pharma, Inc. To Further Develop New Influenza Antiviral Drug, Peramivir
- D-Pharm Successfully Completed Phase IIb Trial of its Neuroprotective Compound (DP-b99) in Acute Stroke Patients
- USFDA Accepted Spectrum Pharma’s IND for Ozarelix and Approved BPH (Benign Prostate Hypertrophy) Phase 2b Protocol
- AspenBio Pharma Submitted Investigational New Animal Drug Application (INADA) to the USFDA’s Center for Veterinary Medicine for StayBred™
- Genaera Corp.’s Restructuring Terminates EVIZON ™ Clinical Program to Pursue Anti-Obesity Research
- MacroGenics and JDRF Sealed Partnership to Support Pivotal Phase II/III Clinical Trial of Anti-CD3 Monoclonal Antibody for Children and Adults with Recent-Onset Type 1 Diabetes
- Medarex Received Milestone Payment from ImClone Systems for IMC-3G3 (Fully Human Antibody for the Treatment of Cancer)
- Exelixis and Genentech Entered Co-development Agreement for Small Molecule Oncology Compound
- Daiichi Sankyo, Inc. Submitted WelChol Supplemental New Drug Application (NDA) for Type 2 Diabetes Mellitus Treatment
- Lupin Pharmaceuticals’ Generic ZOLOFT® Received USFDA Tentative Approval
- BYETTA® (exenatide) Injection, USFDA-Approved for Expanded Combination Use
- Biomira Initiated Phase II Clinical Trial of PX-12 in Advanced Pancreatic Cancer Patients
- Sigma-Aldrich Awarded Pfizer Non-Exclusive Worldwide License to Use ddRNAi in Research Programs
- Graceway Pharmaceuticals, LLC Has Completed Acquisition of 3M Pharmaceuticals Business
- Eli Lilly’s Reaction on the NY Times Zyprexa® Article
- Viragen Inc. Granted Multiferon®’s Exclusive Marketing Rights in Australia and New Zealand to Orphan Australia
- Sontra Medical Corporation is Closing Down
- ThromboGenics and BioInvent Received 2 Million € EU Grant for ANGIOSTOP Anti-Angiogenesis Programme
- Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Initiated Multi-Center Combination Study for the Treatment of Multiple Myeloma
- Threshold Pharmaceuticals’ Glufosfamide Showing Promising Results in (Ongoing) Phase 2 Clinical Trial for Treatment of Pancreatic Cancer
- Stiefel Laboratories, Inc.’s Acquisition of Connetics Corporation, Completed
- Nuvo Research, Inc. Received USFDA Approvable Letter for Pennsaid® (Potential New Treatment for Osteoarthritis of the Knee)
- Boca Pharmacal’s Generic Pamine® and Pamine® Forte Tablets, Approved by the USFDA
- First Generic Versions of Ondansetron Tablets, Orally Disintegrating Tablets and Oral Solution, USFDA Approved
- Pharmaceutical Business Round-up: What We Missed During the Holidays
- Happy New Year
- PharmaGazette Christmas Greetings
- Pharmacyclics' NDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases, USFDA Submitted
- I'm back...
- AEterna Zentaris’ AN-152 Successfully Passed Phase 1 Clinical Trial in Gynaecological and Breast Cancers Patients
- Cytogen Received US Patent Covering Oral Drug Delivery Agents
- Anesiva Submitted USFDA NDA for Zingo™ (Pain Reliever for Needle Insertion Procedures in Children)
- MannKind Corporation’s IND for MKC1106-PP Immunotherapy in Solid Malignancies, USFDA-Cleared
- Mayne Pharma Acquired Remaining Rights to SuperGen Inc.’s Nipent®
- Melbourne-Based Biota Closed US$102 Million License with Boehringer Ingelheim for Hepatitis C Virus (HCV) Program
- Cytokinetics and GlaxoSmithKline Amend Ispinesib (SB-715992) and SB-743921 Collaboration and License Agreement
- Betaferon® Approved in Australia for Early Stage Multiple Sclerosis (MS)
- DRAXIS Radiopharmaceutical Unit, DRAXIMAGE: Received USFDA Approval to Run 2 Clinical Trials for Neuroblastoma Treatment
- AstraZeneca Entered Distribution Agreement With Par Pharmaceutical for Authorized Generic TOPROL-XL® (metoprolol succinate)
- Back from "Thanksgiving" Weekend
- Artemis Agreed With Merck & Co., Inc. In making Genetically Engineered In-Vivo RNAi Mouse Models
- PARI and Kamada Collaboration will Develop Inhaled Alpha-1 Antitrypsin (AAT)
- GlaxoSmithKline, To Supply U.S. Stockpile with bulk H5N1 Antigen
- Sanofi Pasteur, In Contract with the U.S. Government for Stockpile of New Type (clade 2) of H5N1 Pre-Pandemic Vaccine
- BioCryst's Anti-Cancer Drug Fodosine™ Received Orphan Status In Europe
- Pharmacyclics’ Xcytrin® Showed Positive Phase III Trials in Lung Cancer Brain Metastasis
- Target Hemoglobin Range in Most Anemic Chronic Kidney Disease Pre-Dialysis Patients Achieved With PROCRIT® (Epoetin alfa) Therapy Initiated Every Two Weeks
- NPRL2: Introgen’s Novel Nanoparticle Tumor Suppressor Reverses Resistantce to Cisplatin in Lung Cancer Treatment
- Somaxon Pharmaceuticals' SILENOR™ Passed Phase III Insomnia Clinical Trial
- Update on XERECEPT® for Peritumoral Brain Edema, Presented by Celtic Pharma and Neurobiological Technologies at SNO Annual Meeting
- Shire’s Investigational Drug for Adult ADHD: SPD465, Bioequivalent to ADDERALL XR
- Genentech’s Herceptin® USFDA Approved for Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
- Advanced Magnetics’ Ferumoxytol as an Intravenous Iron Replacement Therapeutic, Passed Phase III Clinical Trial
- Novalar Pharmaceuticals’ Local Dental Anesthetic Reversal Agent (NV-101) Passed Phase 2 Clinical Trial in Pediatric Population
- Pfizer Animal Health Agreed to Acquire Embrex, Inc.
- Novel Intranasal Analgesic, ROXRO Pharma’s Ketorolac (ROX-888): Provides Effective Pain Relief
- Vanda Pharmaceuticals' VEC-162 Passed Phase III Clinical Trial on Transient Insomnia
- WelChol® (colesevelam HCl) +Insulin Improves Glycemic Control Uncontrolled Type 2 Diabetes Mellitus Patients: New Study Confirms
- Intensive Lipitor Therapy Reduced Heart Attack and Stroke By One-Third in Chronic Kidney Disease Patients: First Dose-Dependent Lipitor Data Analysis Revealed
- Dangerous Pill: New NABP Anti-Counterfeit Drug Website
- AIDS Healthcare Foundation and CIPLA Discussed Drug Price Reduction Issue in India
- Alba Therapeutics’ Oral Zonulin Receptor (AT-1001) Passed Phase Ib Clinical Trial on Celiac Disease
- Secondary Endpoint Not Met in Favrille’s Phase 3 Clinical Trial of FavId® Following Rituxan® in Follicular B-Cell Non-Hodgkin's Lymphoma (NHL)
- Roche’s ACTEMRA™ (tocilizumab) Significantly Improved Remission Rates in Rheumatoid Arthritis Patients
- New Study Data Revealed that Lilly’s Ruboxistaurin (Arxxant™) Reduced Vision Loss in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy (DR)
- Immunomedics Reported Epratuzumab and Rituximab Modes of Action at the ACR Annual Meeting
- New Study Further Supports Cardiovascular Safety of Over-The-Counter (OTC) Doses of Naproxen Sodium
- Use of Thymoglobulin® is Beneficial than Basiliximab in kidney Transplant Patients
- Pharmacyclics’s Phase 2 Clinical Trial of Xcytrin® With Radiosurgery for Brain Metastases, Showed Positive Results
- Boehringer Ingelheim‘s Mirapex®: USFDA-Approved fro the Treatment of Restless Legs Syndrome (RLS)
- Angiotech's Vascular Wrap™ Passed First Human Trial
- Bavarian Nordic Reported Progress in New Smallpox Vaccine Program
- Perrigo Co. Recalls 11 Million Acetaminophen Bottles
- Anadys Pharma’s ANA975 Under New 13-Week Pre-Clinical Toxicology Study Using Crystalline Form
- NUVIGIL™ Composition of Matter Patent, Granted to Cephalon, Inc.
- Metabolex Received European Patent for Metaglidasen
- Infinity and MedImmune’s Anti-Hsp90 Compound: IPI-504, Showing Promising Biological Activity in Phase I Trial in Gastrointestinal Stromal Tumors (GIST)
- QUADRAMET®’s Combination Study in High-Risk Prostate Cancer Patients, Passed Phase 1 Clinical Trial
- TK Sense(SM): Panacea Pharmaceuticals' Test that Predicts Response to Imatinib (Gleevec®) Therapy in Chronic Myelogenous Leukemia (CML)
- PharmaGazette is The PharmVoice No More
- Special Protocol Assessment (SPA) Approval, Granted by USFDA for Gamida Cell's Stemex® Registration Study
- Acquisition of Kos Pharmaceuticals Will Expand Abbott’s Presence in the Lipid Management Market
- Celgosivir Combination Therapy, Clinically Beneficial in Chronic Hepatitis C Non-Responder Patients
- Poniard’s Picoplatin, Showing Positive Interim Survival Results from Ongoing Phase 2 Trial for Small Cell Lung Cancer
- Two Randomized Clinical Trials of ERBITUX® in Metastatic Colorectal Cancer, Revealed Survival Data
- Introgen Therapeutics Gained Exclusive License to Therapies Combining Epidermal Growth Factor (EGFr) Drugs and Tumor Suppressor Genes
- 2006 Thomas Alva Edison Patent Award for Potential New Therapy for the Prevention of Osteoporosis, Awarded to Wyeth Researchers
- Ispinesib Clinical Data and SB-743921 Non-Clinical Data: To be Presented by Cytokinetics at the 2006 EORTC-NCI-AACR International Meeting
- LEVITRA® Effectively Treated Erectile Dysfunction (ED) at First Dose In Men With Certain Associated Cardiovascular Conditions, New Clinical Data Revealed
- WHO is Launching IMPACT (International Medical Products Anti-counterfeiting Taskforce): A Global Anti-Counterfeiting Plan
- CuraGen and TopoTarget Out-Licensed Worldwide Rights of PXD118490 (Preclinical HDAC Inhibitor) To LEO Pharma
- US National Institutes of Health Picked Evogenix For Anti-Cancer Collaboration
- Inyx, Inc. Sealed Deal with Plethora Solutions for the Production of Novel HFA Aerosol (Treatment for Premature Ejaculation) for U.S. Clinical Trial
- AstraZeneca’s Revised Patient Assistance Program Aims to Help More People Afford Its Medicines
- Oramed Pharmaceuticals Signed Manufacturing Agreement with Swiss Caps AG
- Ranbaxy Received Tentative USFDA Approval to Manufacture and Market Cetirizine Hydrochloride Syrup
- BioMS Medical Receives Additional US Patent for MS Drug MBP8298
- Three New Mycobacterial Cell Wall-DNA Complex (MCC), Granted to Bioniche Life Sciences
- Osteologix Received European Patent for the Treatment of Cartilage and Bone Conditions
- Lpath and Sapient Discovery’s Collaborative Study That Characterized Favorable Interactions of Lpath's Anti-S1P Therapeutic Antibody with Its Target, Successfully Completed
- InViragen and Shantha Biotechnics Entered Into Dengue Vaccine Manufacturing Agreement
- 61.5 % of Study Participants Experienced Hair Regrowth Using the Natural Supplement Nourkrin®
- Lorus Therapeutics Presented GTI-2040 Pharmacokinetic in Acute Myeloid Leukemia at the AAPS Meeting
- CVS Corporation Merges with and Caremark Rx, Inc.
- China Pharma Granted GMP Certification and SFDA Approval for the Production of Cephalosporin
- Dong-A Pharmaceutical Co., Ltd. Agreed with SCP (Saudi Arabia) for the Distribution of Erectile Dysfunction Drug Zydena in (Gulf Cooperation Council) Countries
- Shire plc’s ADHD Patch, DAYTRANA™ (methylphenidate transdermal system): Provided Individualized Symptom Management
- Pharmasset Commenced Phase 1 Study of R7128 for Hepatitis C Virus
- Dendreon’s PROVENGE® Demonstrated Prostate Cancer Survival in Phase 3 Studies
- Telbivudine (TYZEKA™) Data from Idenix’s GLOBE Study, Presented at AASLD Annual Meeting
- Schering –Plough’s INTRON® and REBETOL® Retreatment Study Results, Presented at AASLD Annual Meeting
- NicOx’s Naproxcinod Sucessfully Passed Osteoarthritis Phase 3 Trial
- Strattera®, Effective in Treating ADHD Symptoms in Children and Adolescents with ADHD and Reading Disorders, New Study Says
- European Patent Office Supports Validity of Pfizer's Lipitor® Patent
- Wyeth: One of the U.S. EPA's Best Workplaces for Commuters
- New Drug for the Treatment of Chronic Hepatitis B Patients: Idenix Pharma, Inc.'s TYZEKA™ (telbivudine), USFDA-Approved
- Laureate Pharma Extended its PROSTASCINT® Manufacture Agreement with Cytogen Corp.
- Auxilium Pharmaceuticals, Inc.'s Injectable Enzyme against Peyronie's Disease: AA4500, Passed Phase II Studies
- Javelin Pharmaceuticals: Frost & Sullivan’s Entrepreneurial Company of the Year for Intranasal Therapeutics
- Genmab A/S Initiated Combination Clinical Study of HuMax-EGFr™ With Chemo-Radiation
- Treatment Response to Mesalamine = Rapid Mucosal Healing in Moderately Active Ulcerative Colitis (UC) Patients, According to Combined Data Analysis
- New Nexium® Formulation: NEXIUM® For Delayed-Release Oral Suspension, Approved by the USFDA
- Clinical Data Demonstrating Additive Anti-Fibrotic Combination Effects of Actimmune® and Pirfenidone, Presented by InterMune, Inc. at CHEST 2006
- U.S. District Court Granted Ortho-McNeil Neurologics, Inc.’s Request for Preliminary Injunction for TOPAMAX®
- D-Pharm Ltd. Granted DP-b99 Exclusive License to Yungjin Pharmaceutical Company Ltd. For Korean Acute Stroke Market
- Stiefel Laboratories, Inc. Bought Connetics Corporation
- BrainCells and Organon Entered Collaboration for Discovery and Development of CNS Drugs
- Somaxon Pharmaceuticals' SILENOR™ Passed Phase 3 Transient Insomnia Clinical Trial
- DelSite Presented Clinical Data on Influenza Nasal Powder Vaccine
- Novartis’ Zelnorm® Demonstrated Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
- AMITIZA™ (lubiprostone) Demonstrated Efficacy Within 24 and 48 Hours of Treatment
- VIVUS' Obesity Pill, Qnexa™ Demonstrated Positive Phase 2 Clinical Data
- Prasugrel Achieved Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel in a New Study
- U.S. Appeals Court Denied Ranbaxy’s Petition for Rehearing of Main Patent in Lipitor Case
- Abbott's HUMIRA® (Adalimumab) Induced Clinical Remission in Infliximab-Intolerant/Unresponsive Crohn's Disease Patients, Phase III Data Says
- Schering-Plough’s NOXAFIL® (Posaconazole), USFDA-approved for the Treatment of Oropharyngeal Candidiasis (OPC)
- SkinMedica’s Desonate™ (Desonide) Gel 0.05% USFDA-approved for the Treatment of Atopic Dermatitis
- USFDA Approved Expanded Indication of Berlex, Inc.’s Betaseron®
- New Purdue Biochip Used in Studying Living Cells: A Tool to Speedy Drug Development
- Roche is No. 3 in Science Magazine's list of Top 20 Employers in the Biotech and Pharmaceutical Industry
- PharmaNova Granted Exclusive U.S. License to Depomed for the Use of Extended Release Gabapentin against Hot Flashes
- ELAPRASE™ (idulsulfase) Received Positive Opinion From European Regulatory Agency
- Tm Bioscience Amended License Agreement with Sirius Genomics
- Novocell, Inc. is Creating Insulin-producing Pancreatic Endocrine Cells from Human Embryonic Stem Cells
- Indication of Centocor, Inc.'s REMICADE®, Now Expanded by the USFDA for Ulcerative Colitis
- PTC Therapeutics Awarded USFDA Orphan Products Development Grant for the Development of PTC124 in Duchenne Muscular Dystrophy
- U.S. District Court Granted Mylan a Motion to Dismiss the '909 Patent in the Amlodipine Besylate Litigation
- Cheaper Generics are More Likely to Attract Large Share of Prescription Drug Sales
- Medicines for Malaria Venture, Genzyme Corporation and the Broad Institute Expanded Collaboration For the Discovery of New Malaria Drugs
- Mutual Pharmaceutical Company Filed Counter Suit Against Adams Respiratory Therapeutics on Guaifenesin Case
- Genzyme Corp. and AnorMED Inc. Agreed on Acquisition Terms
- Sanofi- Aventis' Allegra® (fexofenadine hydrochloride) Oral Suspension, USFDA-approved for Treatment of Seasonal Allergy Symptoms and Chronic Idiopathic Urticaria
- Sanofi Aventis' Taxotere® (docetaxel) Injection Concentrate, USFDA-approved for the Treatment of Patients With Head and Neck Cancer
- Merck's JANUVIA™, USFDA Approved for Type 2 Diabetes
- Endo Pharmaceuticals Responded to the Lidoderm® Issue
- Lexicon Genetics Initiated Preclinical Development of LX2931 for Autoimmune Diseases
- Diffusion Pharmaceuticals Completed USFDA-Required Toxicology Studies in Support of TSC Phase I Trials and Closed $1.5 Million Private Placement
- Genta Incorporated’s Genasense® Received Australian Orphan Drug Designation for Advanced Melanoma Patients
- ARICEPT® (donepezil HCl tablets), USFDA-Approved for Full Spectrum Alzheimer’s Disease
- OncoMed Pharmaceuticals Granted USPTO Patent for Identifying Therapeutics Targeting Cancer Stem Cells
- Austrian Patent Office Ruled in Favor of Pfizer On Lipitor Basic Patent
- Serono and Newron Pharma Entered Into Global Development and Commercialization Agreement for Safinamide
- Foamix, Ltd. and Taro Pharmaceutical Industries Ltd Entered Into License Agreement for the Development and Commercialization of Foamix's PerFoam™ 1% for the Treatment of Head Lice
- TyRx Pharma, Inc. Submitted Premarket Application for PIVIT™ CRM: Novel Mesh Pouch Containing Rifampin and Minocycline Designed to Hold and Reduce Bacterial Colonization of a Pacemaker or ICD Pulse Generator
- Neurochem Submitted Complete Response in Lieu of USFDA’s Approvable Letter for KIACTA™
- Human Genome Sciences Reported Positive Interim Quality-of-Life Data From Phase 2B Trial of Albuferon™ with Ribavirin in Treatment-Naïve Hepatitis C Patients
- Medarex and PharmAthene’s Anthrax Therapeutic Valortim™, Passed Phase I Clinical Trial
- Nabi Biopharmaceuticals’ PhosLo® EPICK Study Revealed Positive Results
- Neuren's NNZ-2591, Proved Effective At Memory Loss Reversal
- PDL BioPharma Presented Physician Survey Results on Heart Attack Treatment
- Genta, Inc. Initiated Phase 1 trial of Antisense Drug, G4460, in Advanced Cancer Patients
- CHEM Rx Announced Acquisition Strategy
- Bayer Appointed Independent Investigator for Review of Trasylol® Study Issues
- Isolagen, Inc and the USFDA Has Agreed on Phase III Protocol Design for Isolagen™ Therapy (IT)
- New River Pharmaceuticals, Inc. and USFDA Conducted End-of-Phase II Meeting on NRP290 (Product Candidate for Acute Pain)
- Morphotek Inc Receives $40 Million in Series D Financing Round
- Clinical Data on Selected Cethromycin Trials Presented by Advanced Life Sciences at IDSA Annual Meeting
- Innocoll, Inc. Receives FDA Approval for CollaGUARD™ Collagen-Based Advanced
- Newly Published Data Show Efficacy and Safety of Spracor's Lunesta in Elderly Patients with Insomnia
- USAMRMC Extended Lexicon Genetics' Grant for Spinal Muscular Atrophy (SMA) Research Program
- Peregrine Receives Regulatory Approval in India for New Cotara® Brain Cancer Clinical Trial
- FDA Grants Orphan Drug Designation For Agennix's Talactoferrin Alfa In Renal Cell Carcinoma
- FDA Approves AstraZeneca's NEXIUM® for the Treatment of Zollinger-Ellison Syndrome
- New Sleeping Pill Rozerem Unlikely to Lead to Dependence or Abuse
- Bellicum Pharmaceuticals Entered into Commercial Licensing of ARIAD's ARGENT™ Cell-Signaling Regulation Technology for Development of New Cancer Therapies
- "Humanized" Antibodies May Prevent and Treat Bird Flu
- FDA Grants Tentative Approval to Teva Pharmaceutical's Generic Risperdal
- Roche Seeks European Marketing Authorization for Herceptin Plus Hormonal Therapy for Advanced HER2-Positive Breast Cancer
- Endo Pharmaceuticals Acquires RxKinetix for $20 Million, Gains Rights to RK-0202 Oral Rinse for Oral Mucositis
- FDA Approves Aricept® For Treatment of Severe Alzheimer's Disease
- Indevus Submits New Drug Application for SANCTURA XR Once Daily Drug For Overactive Bladders
- Alfred Mann Institute Established at the Technion-Israel Institute of Technology , Technion Receives $100 Million
- BioAlliance Pharma Receives French Marketing Authorization for Its first Product Loramyc® for the Treatment of Oropharyngeal Candidiasis
- PharmAthene, Inc. Got $1 Million Congressional Appropriation for Continued Development of Anthrax Therapeutic Valortim™
- Modified Inteleukin-1 Receptor Antagonist May Offer Prolonged Osteoarthritis Relief
- LifeCycle Pharma Entered Into Three Distinct Strategic Collaboration Agreements With Global Pharmaceutical Companies
- Psychostimulant Methamphetamine May Reduce Stroke Damage
- More Than 90% of Pliva Shares Tendered to Barr Pharmaceuticals for $2.5 Billion
- Prozac Increases Bone Mass, May Treat Osteoporosis
- Clinical Studies Show Rotigotine Patch Appears to Be a Safe Treatment for Early-Stage Parkinson's Disease
- FDA Approves Colon Cancer Drug Avastin for Treatment of Non-Small Cell Lung Cancer
- Antipsychotic Drugs Found Ineffective For Treating Psychotic Symptoms in Alzheimer's Disease
- Ambrilla Licenses HIV/AIDA Protease Inhibitor Drug Candidate to Merck for $17 Million Plus $215 Million Milestone Fees
- Cephalon, Inc.'s FENTORA™ (fentanyl buccal tablet) for Breakthrough Pain in Patients with Chronic Low Back Pain, Passed Phase III Clinical Trial
- Amarin Corporation plc, Granted USPTO Patent Approval for Miraxion in Huntington's Disease
- GlaxoSmithKLine Submitted Supplemental New Drug Application for Advair Diskus® in COPD
- Novartis Launched 'GALIANT' Study Comparing the Investigational Drug Galvus® and a Leading Class of Oral Anti-Diabetic Medicines (TZDs)
- CV Therapeutics, Inc. Terminated Co-Promotion of ACEON® (perindopril erbumine) Tablets with Solvay Pharmaceuticals, Inc.
- Schering-Plough Files Patent Infringement Lawsuit Against GeoPharma Inc Over Generic Version of Clarinex(R)
- EU Grants Marketing Approval To Schering-Plough's Suboxone Sublingual Tablets for the Treatment of Opioid Addiction
- Theravance Announce Positive Phase III Trials on Telavancin for MRSA Infections
- Dyanavax Shares Rose Following Publication of Pilot Study On the Efficacy of Tolamba Ragweed Allergy Vaccine
- Wyeth Submits NDA and MAA for mTOR Inhibitor Torisel for the Treatment of Advanced Renal Cell Carcinoma
- Edison Pharmaceuticals Collaborate With Brazil's Institute of Vision To Develop Mitochondrial Therapies for Leber's Disease
- deCode Pharmaceuticals Suspends Phase III Trial of Heart Attack Drug DG031 Due to Formulation Issues
- GW Pharmaceuticals Announce Positive Phase II Trials of Sativex Oromucosal Spray for Multiple Sclerosis
- Out of The Storm Debris
- Sanofi-Aventis U.S. LLC’s Dermik Laboratories Submitted USFDA Supplemental Premarket Approval Application (s-PMA) for Sculptra®
- Nastech Pharma Co. Inc. Initiated Clinical Development of Rapid Acting Diabetic Insulin Nasal Spray
- Cardinal Health Agreed to Scale-Up and Manufacture Clinical Supplies for Bentley Pharmaceuticals, Inc.'s Intranasal Insulin Program
- Sigma-Aldrich Corp. Reached Settlement with Enzo
- ExonHit Therapeutics and Allergan, Inc. Extended Strategic Alliance
- Serono's Oral Cladribine, Granted USFDA Fast Track Status for the Treatment of Multiple Sclerosis (MS)
- Serono, To be Acquired by Merck KGaA
- Debiopharm Group’s Debio-0513 (PTR-262) Received European Orphan Drug Status for Myasthenia Gravis (MG)
- Top 8 Medicinal Products in My Toddlers’ Cabinet
- Chromos and Y's Theraputic Agreed on Cell Line Engineering Contract
- ChemBridge Corporation and ChemBridge Research Laboratories, Inc. (CRL) Entered Into Strategic Alliance on Discovery Chemistry with AstraZeneca
- MannKind Corp.’s Technosphere® Insulin System, Showed Safety and Efficacy in Phase III Clinical Trial in Type 2 Diabetes Patients
- CoFactor®/ Uftoral® (UFT) Combination Showed Positive Results in Colorectal Cancer Model
- Itax (Itopride) Fails Phase III Clinical Trials, Axcan Pharma Shares Fall
- Long-term Alendronate (Bisphosphonate) Use in Patients with Osteoporosis Do Not Increase Vertebral Microcracks
- Tranzyme Pharma Expands Clinical Program of Post-Operative Ileus Drug Candidate, TZP-101, to Include Patients with Gastroparesis
- Sebivo (Telbivudine) Approved in Switzerland for Chronic Hepatitis B
- Altana AG Sells Pharmaceutical Business to Nycomed
- Hospira Agrees to Buy Mayne Pharma Limited for $2 Billion
- Nucryst Pharmaceutical's NPI 32101 Drug Candidate Against Atopic Dermatitis Fails Phase II Clinical Trials
- Wal-Mart to Cut Prices On Almost 300 Generic Prescription Drugs, Drugstore chains Shares Falls
- Angiotech Pharmaceuticals Presents Positive Preclinical Study On Vascular Wrap ™ Paclitaxel-Eluting Mesh for Inhibiting Neointimal Hyperplasia
- BioMarin Completes Enrollment for Phase II Clinical Trials of 6R-BH4 for Treatment of Hypertension
- Novogen's Investigational Cancer Drug Phenoxodiol Targets Prostate Cancer Protein
- Five Wyeth Research Scientists: Honored by Science Spectrum Magazine
- Fosrenol Approved in Germany, AnorMed Receives $3 Million Milestone Payment
- Jury Favored Wyeth in Hormone Therapy Case v. Linda Reeves
- ZymoGenetics Reported the Positive Results of Phase 3 Trial Evaluating rhThrombin as a Potential Treatment for Surgical Bleeding
- Schering-Plough’s NOXAFIL® (Posaconazole): USFDA-Approved for the Prevention of Invasive Fungal Infections (IFIs)
- GlaxoSmithKline Submitted USFDA NDA of Tykerb® (Lapatinib Ditosylate) for Advanced Breast Cancer Treatment
- Serono and Syntonix Pharmaceuticals, Inc Joined Forces to Pursue Development of a Long-Acting, Inhaleable FSH Therapy for the Treatment of Infertility
- Cell Therapeutics Inc. and Novartis Entered Worldwide License and Co-Development Agreement to Develop and Commercialize XYOTAX™
- Pfizer and TransTech Pharma Agreed to Develop and Commercialize RAGE (Receptor for Advanced Glycation End products) Modulators
- Somanta Pharmaceuticals Completed SEC Registration and Received Stock Trading Symbol
- Pharmion Corporation and MethylGene, Inc. Initiated Phase II Clinical Trial of Proprietary HDAC Inhibitor MGCD0103 in B-Cell Lymphomas
- Schering AG and AstraZeneca Entered Strategic Alliance to Develop SERDs: Novel Anti-Cancer Drug
- GlaxoSmithKline’s DREAM Trial Revealed Avandia® (rosiglitazone maleate) Reduced Risk of Progression from Pre-Diabetes to Type 2 Diabetes by 62 Percent Relative to Placebo
- Unimed Pharmaceuticals, Inc. Settled Pending AndroGel® Patent Litigation with Watson Pharmaceuticals, Inc. and Paddock Laboratories/Par Pharmaceutical Companies, Inc.
- Dutch Court Ruled in Favor of Pfizer, Inc. Upholding Basic Lipitor Patent and Preventing Launch of Ranbaxy Generic Version Before November 2011
- Vical, Inc. Received Extended Patent Coverage for Vaxfectin™ Adjuvant to Conventional Vaccines
- Bristol-Myers Squibb Company and Medivir AB Entered Worldwide Collaboration to Develop and Commercialize MIV-170 for the Treatment of HIV-1 Infection in Adults
- Transition Therapeutics Inc. and JDRF Partnered for the Development of Diabetes Regenerative Product GLP1-I.N.T.™
- Cardiome Pharma Corp.’s Oral RSD1235 Passed Phase 2a Pilot Study
- Radius and Karo Bio Entered Into Licensing Agreement for Novel SARM Compounds
- VIRTUE, Largest Clinical Trial of Subcutaneous Immunoglobulin (Ig) Therapy: Launched and Now Open to Primary Immunodeficiency (IP) Patients Across the United States
- KV Pharmaceutical Co. Received USFDA ANDA Approval To Market Six Strengths of Diltiazem HCl ER Capsules (Generic Tiazac®)
- BioMarin and Serono Announced Positive Clinical Trial Results of Phenoptin™ in PKU to be Presented at the 56th Annual Meeting of ASHG
- Ortec International Inc. Announced Positive Results of Orcel® in Confirmatory Venous Leg Ulcer Trial
- Neurocrine Biosciences, Inc.’s Orally Active GnRH Receptor Antagonist in Endometriosis (NBI-56418) Passed Follow-Up Phase II Study
- Peter R. Dolan Left Bristol-Myers Squibb as CEO, James M. Cornelius Appointed by Board of Directors as Interim CEO
- Douglas Laboratories Canada: Acquired by Atrium Biotechnologies, Inc.
- Positive Genotoxicity Studies of Somaxon Pharmaceuticals’ SILENOR™ May Lead to its USFDA NDA for the Treatment of Insomnia
- Biomarin Pharmaceutical Inc. Announced Promising Preclinical Outcome of Phenylase™ (Enzyme Substitution Therapy For PKU)
- Acuity Pharmaceuticals Announced the Positive Phase II Results for Bevasiranib in Wet AMD
- Ranbaxy’s Ohm Laboratories, Inc. Received USFDA Approval to Manufacture and Market Loperamide Hydrochloride and Simethicone Tablets (Generic Imodium® Advanced)
- CIP-Tramadol Fails Phase III Clinical Trials, Cipher Pharma Stocks Plunges 24 Percent
- Synta Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results for STA-4783 in Metastatic Melanoma
- Introgen Therapeutics, Inc. and Gendux AB’s ADVEXIN Therapy, Granted EU Orphan Designation
- Abbott Submitted Both U.S. and E.U. Regulatory Applications for the Approval of HUMIRA® (Adalimumab) as Treatment for Crohn's Disease
- Northwest Biotherapeutics, Inc., USFDA-Cleared to Proceed Lung Cancer Trial of DCVax®-LB Personalized Therapeutic Vaccine
- Jazz Pharmaceuticals Initiated Phase III Clinical Trial of Xyrem® (Sodium Oxybate) in Fibromyalgia Syndrome Patients
- ExonHit Therapeutics S. A.’s RNA Splicing Microarray Patent Rights, Licensed to Merck & Co., Inc.
- GTx, Inc. Entered Partnership Agreement with Ipsen for Acapodene®’s European Rights
- Introgen Therapeutics, Inc.’s ADVEXIN Therapy (p53 tumor suppressor) Showing Potential in Breast Cancer Treatment
- Nextrials, Inc.’s Co-Founder Will Discuss Benefits of Integrating Electronic Healthcare and Clinical Trial Data at ExL Pharma's Second Annual Merging Electronic Health Records (EHR) and Electronic Data Capture (EDC) Conference
- STEEPLE Study Revealed Superior Safety Profile of Sanofi-Aventis’ LOVENOX® (Enoxaparin Sodium Injection) Over Unfractionated Heparin (UFH) in Non-Emergent Percutaneous Coronary Intervention (PCI) Patients
- Annual Merging Electronic Health Records (EHR) and Electronic Data Capture (EDC) Conference
- Labopharm Inc. Presented at the Clinical Meeting of American Academy of Pain Management, the Safety Data from 3 U.S. Phase III Trials for Once-Daily Tramadol
- Review Period for Shire plc’s MESAVANCE™ (mesalamine) NDA, Extended by USFDA
- In Product Acquisition Agreement with Ligand Pharmaceuticals: Eisai, Inc. Gains Four Oncology-Related Products
- EuroPharma Entered Exclusive Agreement with New Chapter for the Distribution of Vectomega® Into Health Food/Natural Product Retail Channel
- Manufacture of OVATION Pharmaceuticals, Inc.’s Panhematin® (hemin for injection) at Cardinal Health, Inc.’s New Facility, Received USFDA Approvable Letter
- Cordis Endovascular’s CYPHER SELECT™ Sirolimus- eluting Stent: First Drug-Eluting Stent Approved in Europe for Most Severe Form of Leg Arterial Disease
- Pfizer’s Lipitor® Found More Effective Than Simvastatin® in Reducing Risk of Additional Heart Attacks in Patients Who Had a Recent Heart Attack
- Lentigen Corporation Signed Second Collaborative Research Agreement with the University of Pennsylvania
- SkyePharma and Mundipharma Entered Exclusive Licence Agreement for European Marketing and Distribution of Flutiform™
- U.S. Court of Appeals favored Mylan Laboratories, Inc. in Oxybutynin Patent Litigation
- Watson Pharmaceuticals’ Generic Seasonale®, USFDA Approved
- FDA Advisory Committee Gives Negative Review on Genta Incorporated's Genasense® for Treatment of Chronic Lymphocytic Leukemia
- Dynavax and AstraZeneca to Co-Develop TLR-9 Agonists for Asthma and COPD
- Claris LifeSciences to Expand in Europe, Ties up with STADA Arzneimittel Subsidiaries
- Pfizer Won Norvasc Patent Against Synthon Pharmaceuticals
- Tentative Approval For Clobetasol Propionate Foam (Generic Olux® Foam, 0.05%) Granted to Perrigo
- Sabinsa Corp.’s Ocufors™, Approved for Indian Market and Manufacturing
- Debiopharm and Salix Pharmaceuticals Signed SANVAR® IR (Immediate Release Formulation) License Agreement
- Anthera Pharmaceuticals Acquires Rights to Anti-Inflammatory Drug Portfolio Developed By Eli Lilly and Shionogi
- ZymoGenetics Reports Positive Phase 3 Clinical Trial Results of Recombinant Thrombin
- EpiCept's LidoPAIN SP Analgesic Patch Fails European Phase III Trial
- Cenestra Health Releases High-Purity Omega-3 Fatty Acid Supplement
- Rheumatoid Arthritis Drugs May Be More Efficient If Delivered Into the CNS
- Sanofi pasteur Started Shipment of Fluzone®, Influenza Virus Vaccine
- Plavix® Patent Infringement Case’s Preliminary Injunction, Ordered Apotex to Stop Sales of Generic Plavix®
- Emergent BioSolutions Awarded Two NIAID Grants to Support Development of Anthrax Immune Globulin (AIG) Therapeutic Product
- Exelixis, Inc. Submitted USFDA IND for Novel Anticancer Compound, XL228
- Velcura Therapeutics, Inc., Awarded NIA SBIR Grant for More Research on Human Bone Formation Processes
- Vanda Pharmaceuticals, Inc. Successfully Completed Enrollment of Volunteers for its Iloperidone and VEC-162 Phase III Trials for Treatment of Schizophrenia and Insomnia, Respectively
- Mylan Lab Inc.’s Fluoxetine Capsules, USP, Granted USFDA Tentative Approval
- Lentigen Corp. and Dharmacon, Inc. Joint Forces to Develop Custom Lentiviral Reagents for RNAi Research
- Nastech Pharma Co. Inc. Received Development Grant for siRNA Therapeutics for the Prevention and Treatment of Influenza
- Purdue Pharma L.P. and Teva Pharmaceuticals Agreed to End OxyContin® Patent Lawsuit
- Emergent BioSolutions, Inc.’s BioThrax® (Anthrax Vaccine Adsorbed), Certified by U.S. Department of Homeland Security As An Approved Product For Homeland Security
- Sinovac Biotech Annouces Positive Phase I Trials of H5N1 Influenza Vaccine, Prepares for Mass Production
- Ranbaxy Won Two Additional Norwegian Patents for Atorvastatin
- Pharmexa Receives Approval In France To Initiate Phase II Trial with GV1001 in Liver Cancer
- European Commission Approves Novartis' Exjade Oral Iron Chelator
- USFDA Accepts Hana Biosciences' New Drug Application For Zensana Oral Spray
- Millenium Pharmaceuticals Initiates Phase I Trials for MLN0415 Drug Candidate Against Inflammatory Diseases
- Compound Solutions Entered CoQ10 Agreement with Premier Chinese Manufacturer, HZH Pharmaceutical
- Allos Therapeutics, Inc. Initiated Phase 2 Study of PDX (Pralatrexate) in Peripheral T-cell Lymphoma Patients
- Chemokine Therapeutics, Granted US Patent on Chemokine Analogs for the Treatment of Various Human Diseases
- MedImmune, Inc. and Infinity Pharmaceuticals, Inc. Entered Development and Worldwide Commercialization Agreement Announce of Novel Small Molecule Cancer Drugs
- Paramount Acquisition Corp. Acquires Major Interest in BioValve Technologies, Inc.’s Valeritas, LLC
- Genentech and Biogen Idec, Inc.’s Rituxan® Passed Phase II Trial in Relapsing-Remitting Multiple Sclerosis (RRMS)
- SGX Pharmaceuticals, Inc.’s Phase II/III Clinical Trial of Troxatyl™ in Acute Myelogenous Leukemia, Discontinued
- Mylan Laboratories To Acquire Up to 71.5% of India-Based Matrix Laboratories
- Endo Pharmaceuticals Settles Patent Case, Will Cease Generic OxyContin Sales
- Nabi Biopharmaceuticals Acquires Exclusive Rights to Novel Plasma Fractionation Technology from ProMetic Life Sciences
- StemCells, Inc. Enters Licensing Agreement With Stem Cell Therapeutics Over Adult Neural Stem Cell Therapeutics
- Novogen, Ltd. Ends Financial Year with Solid Cash Reserves and USFDA Clearance for Phase III Human Trial of Phenoxodiol
- Dendreon Corp. Partially Completes Rolling USFDA BLA of PROVENGE® as Treatment for Advanced Prostate Cancer Patients
- Shire plc Submitted Guanfacine Extended Release NDA for the Treatment of ADHD in Children and Teens
- Nanogen, Inc. Acquired 6 Patents for Detection and Use of Biomarkers Related to Diabetes and Alzheimer’s disease
- Neurobiological Technologies, Inc. Completes Targeted U.S. Site Selection for Its First Phase III Clinical Trial of Viprinex™ (Ancrod Injection) in Acute Ischemic Stroke Patients
- Study Shows Unfractionate Heparin Just As Effective as Low-Molecular Weight Heparin in the Treatmetn of Venous Thromboembolism
- Lpath, Inc. Received Allowance of Patent Claims for Anti-Cancer Drug, Sphingomab™
- Corcept Therapeutics, Inc.’s CORLUX®, Failed First of 3 Phase III Studies for Treating the Psychotic Features of Psychotic Major Depression
- Acuity Pharma, Inc. and Pathogenics, Inc. Announced Positive Preclinical Data of N-Chlorotaurine (NCT) in Viral Conjunctivitis (Pink Eye)
- IdeaSphere, Inc. Acquires Boehringer Ingelheim's Pharmaton SA (Lugano)
- Boehringer Ingelheim Pharma, Inc.’s Mirapex® Showed Positive Results Against Depressive Symptoms in Parkinson's Disease Patients
- Keppra® Granted European Approval As Monotherapy For Partial Onset Seizures in Patients with Epilepsy
- MedImmune Files Investigational New Drug Application for MT103 Against non-Hodgkins Lymphoma
- HIV Drug Lopinavir Also Effective Against Human Papilloma Virus (HPV)
- sNDA for Mission Pharmacal’s Tindamax® (Tinidazole) as Treatment of Bacterial Vaginosis (BV), Submitted to the USFDA
- UCB Group, Inc.’s Keppra®, USFDA Approved as Adjunctive Therapy in the Treatment of Myoclonic Seizures in Juvenile Myoclonic Epilepsy Patients
- XYOTAX™ (Paclitaxel Poliglumex) + Concurrent Radiation Produces= Promising Tumor Responses in 91% of Esophageal or Gastric Cancer Patients
- Mayne Pharma Limited Completes Purchase of SuperGen Inc.'s North American Oncology Products
- Stiefel Laboratories, Inc. Bagged Licensing Agreement with Italian Companies
- Medarex and GenPat77 Entered Therapeutic Antibody Co-Development Agreement
- ARIAD Pharmaceuticals Obtains Patent For AP23573 mTOR Inhibitors and Its Use in Cancer Treatment and Restenosis
- FDA Approves Barr Pharmaceutical's Plan B Contraceptive for OTC Sale
- Wyeth and Progenics Pharmaceuticals Initiated Phase 2 Clinical Trial of Oral Methylnaltrexone
- Neuren Pharmaceuticals’ Glypromate®, Passed Phase 2a Clinical Trial
- Now Insulin Inhaler, Tomorrow Insulin Pill
- Entelos Signs Research Collaboration with Novartis AG
- Isotechnika, Inc.’s TAFA93, Passed Phase 1a Clinical Trial
- Changes to Dexedrine®’s Boxed Warnings and Precautions, Announced by the USFDA and GlaxoSmithKLine
- Althea Technologies, To Manufacture Altus Pharmaceuticals’ ALTU-238 for Phase III Trial
- Quigley Pharma Received Second Patent Covering Peripheral Neural and Vascular Complaints for QR-333, Its Lead Investigational New Drug Formulated for Diabetic Neuropathy
- Athenagen, Inc. Initiated First Human Trial of Novel Anti-angiogenic Therapy (ATG003) for AMD
- CoGenesys, Inc. Entered Worldwide License Agreement with Vegenics Ltd.
- ABILIFY® DISCMELT™(aripiprazole): New Rapidly Disintegrating Oral Form of Antipsychotic Medication ABILIFY® (aripiprazole), Launched by Bristol-Myers Squib Co. and Otsuka Pharma Co.
- Xenogen Biosciences Entered Into a Target Validation Collaboration Agreement with Schering-Plough
- China Biopharmaceuticals Completed All Clinical Trials for Nafamostate Mesilate
- Isolagen Acquired 57% Interest in Agera Laboratories, Inc.
- United Research Laboratories/Mutual Pharmaceutical Company Filed USFDA ANDA for Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg
- Eli Lilly & Co.’s NDA for Arxxant™ (ruboxistaurin mesylate) for the Treatment of Diabetic Retinopathy, Received USFDA Approvable Letter
- Bristol-Myers Squibb Co. and Sanofi-Aventis SA, Trying to Block Generic Plavix
- Caraco Pharma Lab Ltd.’s Baclofen Tablets, Received USFDA Final Approval
- Sirion Therapeutics, Inc. Merged With Sytera, Inc.
- SOLTAMOX™: First Oral Liquid Formulation of Tamoxifen for Breast Cancer Patients, Launched by Cytogen Corp. in the US Market
- Northwest Biotherapeutics’ Phase II Clinical Trial of its DCVax®-Brain in Patients with Brain Cancer, to be managed by Synteract
- Iomai Corp. Initiates Phase 2 Clinical Trial of Travelers' Diarrhea
- Transport Pharma's Drug/Device Combination Product for Herpes Labialis, SoloVir™, Passed Phase IIb Clinical Trial
- Novartis Seek European Approval for Diabetes Drug Galvus (Vildagliptin)
- ProEthic Pharmaceuticals Announce Positive Phase I Trials For Rapid Release Diclofenac
- ViroPharma and Wyeth Achieved Proof of Concept Milestone for HCV-796 (Investigational Oral Non-nucleoside Hepatitis C Virus (HCV) Polymerase Inhibitor)
- NBTY, Inc. to Acquire Manufacturer and Marketer of Ester-C®: Zila Nutraceuticals, Inc.
- Intranasal Therapeutics Closes $39.1 Million Series A Venture Financing
- Akzo Nobel to Spin-off Organon Biosciences, Shareholders to Vote on September 7
- VaxGen, Inc. Published Results of its Phase I Clinical Trial of Anthrax Vaccine Candidate, rPA102
- Schering-Plough and Novartis Collaborates to Develop Once-Daily Combination Therapy for Asthma and COPD
- USFDA Expanded REMICADE® Psoriatic Arthritis Indication
- Additional Safety and Efficacy Data for PREZISTA™ as Part of HIV Combination Therapy, Presented at the 2006 AIDS Conference
- Bioponic Phytoceuticals, Inc.’s Flight Spray® Can Fly: Exempted from the TSA Terrorist Plot Ban
- Potentia Pharma Inc. Entered Worldwide License Agreement To Develop and Market University of Pennsylvania’ Complement Inhibitor Against All Forms of Age-related Macular Degeneration (ARMD)
- Publications to Watch: Analysts Media’s Future Pharmaceuticals and Future Healthcare
- eCommunication and Online Marketing Conference
- CuraGen Corp. and TopoTarget A/S Initiated Phase I Clinical Trial of PXD101 in Combination with Azacitidine in Patients of Advanced Hematologic Cancers
- Bioheart, Inc. Acquired Worldwide Exclusive Rights to Tissue Genesis' Cell Technology for the Treatment of Acute Heart Attacks
- Arthritis Drug Anakinra, Helps Relieve Debilitating Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
- Boston Life Sciences, Inc., Harvard Granted U.S. Patent on Methods for the Diagnosis and Monitoring of ADHD
- Cure HIV, Inc. and Global Humanceuticals, Inc. Working Together on International Patent and Marketing of Cheap, Topical Microbicide against HIV
- Medicure Acquired Rights to Cardiovascular Drug Aggrastat for $19 Million
- Encysive Pharmaceuticals Receive European Marketing Approval For Pulmonary Arterial Hypertension Drug, Thelin®
- Genzyme Filed European Approval of Synvisc® In Ankle and Shoulder Indications
- Cell Therapeutics, Inc.’s Pixantrone Passed Phase III Trial
- Quigley Pharma Inc.’s QR-443 Found Effective in Prevention of Cachexia
- Novartis MeNZB™ Vaccine Campaign against Epidemic Meningococcal B Disease Outbreak in New Zealand, Successfully Concluded
- Phase III Pivotal Efficacy Study Protocol for Abeille Pharma Inc.’s AB-1001, Submitted to the USFDA for Review
- Anacor Pharmaceticals’ Topical Antifungal, AN2690, Passed Phase 1 Clinical Trial
- American Kidney Fund and Genzyme Corp. Offers Renagel® To Patients Under the New Medicare Part D Assistance Program
- Advancis Pharma Announces Positive Phase III Trial Results for Once-Daily Amoxicillin PULSYS Against Streptococcal Infections
- Top Ten Pharma Product Websites Visited by US Doctors
- MacuSight, Inc.’s IND for Novel Ophthalmic Drug Candidate (Sirolimus), Accepted by the USFDA
- Epeius Biotechnologies’ Rexin-G™ Granted Accelerated Approval in the Philippines for the Treatment of Solid Tumors
- Alzheimer's Drug, Galantamine: Potential Antidote against Nerve Agent and Pesticide Poisoning
- Gilead Sciences, Inc. Hands Over Trade Secrets to Get AIDS Drugs to Poor Countries
- Seventh Annual Pharmaceutical Regulatory and Compliance Congress
- Cheap Generic Tamiflu, Made by Thais to Secure Country’s Stockpiles
- Ingenix, Inc. Acquires NWH, Inc.
- Radius Acquired Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists
- MicroIslet, Inc.’s Transplantation Studies in Diabetic Primates, Reported Successful at Six-Month Milestone
- Novogen Limited’s Investigational New Drug for Inflammatory Bowel Disease, NV-52, Enters Second Human Clinical Trial
- TorreyPines Therapeutics Inc.’s NGX426 (Novel Oral Therapy for Migraine and Neuropathic Pain)’s Phase 1 Clinical Trial, Initiated
- BioCryst Received USFDA Special Protocol Assessment (SPA) To Initiate Pivotal Trial of Fodosine™ in T-Cell Leukemia
- Corcept Therapeutics Inc.’s CORLUX® Passed Phase 2 Study for the Treatment of Psychotic Major Depression (PMD)
- Bionovo, Inc. Reported the Potential of Selective Estrogen Receptor (ER) Beta Compounds as Safer Treatments for Menopausal Symptoms
- Mayne Pharmaceutical's Cancer Drug Oxaliplatin, Approved for Marketing in Portugal
- Predix Pharmaceuticals Begins Phase II Clinical Trials for Pulmonary Hypertension Drug Candidate
- FDA Grants Fast Track Designation to Novelos Therapeutics' Lung Cancer Drug Candidate
- Napo Pharmaceuticals, Inc.’s Crofelemer, Approved in India to Commence Phase II Clinical Trial for Acute Infectious Diarrhea in Adult Patients
- AEterna Zentaris Entered into a License and Collaboration Agreement with Nippon Kayaku to Market Ozarelix in Japan
- Clinical Trials Demonstrate Dutasteride Effective in Treating Enlarged Prostate
- Eli Lilly's Strattera Effective In Long-Term Treatment of Attention Deficit Hyperactivity Disorder in Adolescents
- Pharmaceutical Firms Prefer Outsourcing in China Over India
- Annual Drug Delivery Technologies & Deal-Making Summit
- China Biopharmaceuticals Holdings, Inc. Submitted AMEX Application
- PDL BioPharma, Inc.’s Terlipressin Failed Phase 3 Clinical Study in Treatment of Type 1 Hepatorenal Syndrome (HRS)
- Allos Therapeutics, Inc. Received USFDA Special Protocol Assessment (SPA) for its Novel Antifolate PDX’s Pivotal Phase 2 Study in Patients with Peripheral T-cell Lymphoma
- Archemix Corp. and Nuvelo, Inc. Expands Collaboration Agreement, Nominates New Clinical Compound
- Amorfix Life Sciences and Biogen Idec To Collaborate on Developing Drugs for Amyotrophic Lateral Sclerosis
- GlaxoSmithKline’s LAMICTAL® (Lamotrigine): Effective as Adjunct Therapy for Children and Adolescents with Primary Generalized Tonic-Clonic (PGTC) Seizures
- ISTA Pharmaceuticals, Inc. Acquired Exclusive North American Rights to Investigational Ophthalmic Therapy for Allergic Conjunctivitis (Senju Pharma Co., Ltd.’s Bepotastine)
- Baxter’s ADVATE®, Approved by Health Canada
- Cerexa Inc.’s Ceftaroline Passed Phase 2 Clinical Trial for the Treatment of cSSSI
- AEterna Zentaris Inc.’s Ozarelix (D-63153) Passed Phase 2 Clinical Trial in Hormone-Dependent Inoperable Prostate Cancer
- Transition Therapeutics, Inc.’s Alzheimer's Disease Drug Product AZD-103, Cleared by the USFDA to Initiate Phase I Clinical Trial
- FDA Warning: Don’t Drink High-Strength Hydrogen Peroxide (even) for Medicinal Use
- Schering Receives Canadian Approval for Betaferon as Treatment for Early Stage Multiple Sclerosis
- Raptor Pharmaceutical Inc. Entered Research Collaboration with Stanford University to Study Use of NeuroTrans™ (Therapeutics Delivery across the Blood-Brain Barrier)
- GPC Biotech Initiates Phase 2 Randomized Trial Evaluating Satraplatin plus Tarceva® for Treatment of Advanced Non-Small Cell Lung Cancer
- Dendreon Corp.’s Construction of New Jersey Manufacturing Facility for PROVENGE®, Completed
- FDA Approves UCB's Intravenuous Keppra® As Adjunct Therapy for Epilepsy
- AstraZeneca and Pozen Inc To Co-Develop And Commercialize Drugs for the Treatment of Chronic Pain
- CHDI and Edison Pharmaceutical to Collaborate on Developing CoQ Analogs For the Treatment of Huntington's Disease
- Ohm Labs Inc. (a Ranbaxy Laboratories Limited subsidiary) Bagged Prestigious 'Private Label Supplier of the Year Award' from AmerisourceBergen
- Alfacell Corporation’s AC 03-636, Demonstrated Promising Antiviral Activity
- Pfizer's Smoking Cessation Drug Chantix, Now Out in the Market
- V Therapeutics, Inc.‘s CVT-6883, Demonstrated In Preclinical Study Potential Ability in Treating Pulmonary Conditions
- FDA May Approve PlanB contraceptive Pill For Over-the-Counter Sale to Women Aged 18 and Above
- Schering AG, Germany’s Sargramostim Passed Phase II Trial (but not the Phase III) in Crohn's Disease Patients
- Takeda and BioNumerik’s Phase III Trials on Tavocept™ did not Meet Primary Endpoints
- XELOX (Xeloda® + Oxaliplatin) and Avastin® Passed (International) Phase I